PCOS renamed PMOS, aiming to improve diagnosis and care

Rochelle Lewis is one of more than 170 million women worldwide living with a condition that has often been misunderstood in exam rooms and in research labs. The Endocrine Society has now given it a new name, Polyendocrine Metabolic Ovarian Syndrome, or PMOS, in an effort to make the disorder easier to recognize, diagnose and treat.

The change is meant to correct a label that many specialists say has narrowed attention to the ovaries and obscured the broader disease burden. PCOS, short for polycystic ovary syndrome, is a common hormonal disorder that affects an estimated 10% to 13% of reproductive-aged women worldwide, and the American College of Obstetricians and Gynecologists says it affects up to 13 in 100 women of reproductive age in the United States. It can cause irregular menstrual periods, abnormal ovulation, infertility, excess facial or body hair and acne, and it is linked to higher risks of diabetes and cardiovascular disease.

That mismatch between name and disease has fueled decades of delay. The syndrome was first described in 1935, then redefined by the Rotterdam consensus in 2003, which broadened diagnosis beyond the earliest criteria. Still, advocates and clinicians say the old term kept many patients from being taken seriously when they reported symptoms that did not fit a narrow image of ovarian cysts. ACOG also says PCOS affects all areas of the body, not just the reproductive system, underscoring why a purely gynecologic label has fallen short.

The renaming effort took 14 years of global collaboration and brought together 56 patient and professional organizations, including Verity, the UK PCOS charity. Helena Teede led the process, with international co-leads Terhi Piltonen of Oulu, Finland, and Anuja Dokras in the United States. Rachel Morman, chair of Verity, said the new name better reflects the hormonal and metabolic nature of the condition.

Beyond terminology, the shift is about access. Women’s health is central to universal health coverage, health equity and gender equality, according to the World Health Organization, and the label attached to a disorder can shape whether symptoms are believed, which studies get funded and how quickly patients get care. For patients like Lewis, PMOS is intended to do more than rename a syndrome. It is meant to make a long-misread condition harder to ignore.